Lam Research Co. (NASDAQ:LRCX) Insider George M. Schisler Sells 400 Shares

Lam Research Co. (NASDAQ:LRCX) insider George M. Schisler sold 400 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $908.21, for a total value of $363,284.00. Following the completion of the sale, the insider now owns 5,661 shares of the company’s stock, valued at approximately $5,141,376.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Lam Research Price Performance

NASDAQ:LRCX opened at $914.91 on Wednesday. Lam Research Co. has a one year low of $512.09 and a one year high of $1,007.39. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.84 and a current ratio of 2.82. The firm has a market cap of $119.62 billion, a price-to-earnings ratio of 33.65, a PEG ratio of 2.82 and a beta of 1.51. The firm’s fifty day moving average is $940.71 and its two-hundred day moving average is $824.74.

Lam Research (NASDAQ:LRCX) last posted its quarterly earnings results on Wednesday, April 24th. The semiconductor company reported $7.79 EPS for the quarter, beating the consensus estimate of $7.26 by $0.53. Lam Research had a net margin of 25.35% and a return on equity of 45.96%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.72 billion. During the same period in the prior year, the company earned $6.99 earnings per share. The firm’s revenue was down 2.0% on a year-over-year basis. Research analysts expect that Lam Research Co. will post 29.62 EPS for the current year.

Institutional Investors Weigh In On Lam Research

Several hedge funds have recently added to or reduced their stakes in the business. DSM Capital Partners LLC purchased a new stake in shares of Lam Research during the 4th quarter worth about $28,000. Valued Wealth Advisors LLC purchased a new stake in shares of Lam Research during the 4th quarter worth about $30,000. Orion Capital Management LLC purchased a new stake in shares of Lam Research during the 3rd quarter worth about $25,000. Partnership Wealth Management LLC purchased a new stake in shares of Lam Research during the 4th quarter worth about $33,000. Finally, Ulland Investment Advisors LLC acquired a new position in shares of Lam Research during the 1st quarter worth about $42,000. 84.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Barclays boosted their price target on Lam Research from $825.00 to $865.00 and gave the company an “equal weight” rating in a report on Thursday, April 25th. UBS Group upped their price target on Lam Research from $1,130.00 to $1,150.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Stifel Nicolaus upped their price target on Lam Research from $950.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Tuesday, April 16th. StockNews.com downgraded Lam Research from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Deutsche Bank Aktiengesellschaft began coverage on Lam Research in a research report on Thursday, April 11th. They set a “hold” rating and a $1,000.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $950.85.

About Lam Research

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.